Free Trial
NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Price, News & Analysis

AbCellera Biologics logo
$4.01 -0.24 (-5.65%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.07 +0.06 (+1.50%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AbCellera Biologics Stock (NASDAQ:ABCL)

Key Stats

Today's Range
$4.00
$4.27
50-Day Range
$1.97
$4.25
52-Week Range
$1.89
$4.33
Volume
5.62 million shs
Average Volume
3.49 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

AbCellera Biologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

ABCL MarketRank™: 

AbCellera Biologics scored higher than 49% of companies evaluated by MarketBeat, and ranked 584th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    AbCellera Biologics has only been the subject of 4 research reports in the past 90 days.

  • Read more about AbCellera Biologics' stock forecast and price target.
  • Earnings Growth

    Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AbCellera Biologics is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AbCellera Biologics is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AbCellera Biologics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about AbCellera Biologics' valuation and earnings.
  • Percentage of Shares Shorted

    13.58% of the float of AbCellera Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    AbCellera Biologics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in AbCellera Biologics has recently increased by 14.71%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    AbCellera Biologics does not currently pay a dividend.

  • Dividend Growth

    AbCellera Biologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.58% of the float of AbCellera Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    AbCellera Biologics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in AbCellera Biologics has recently increased by 14.71%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    AbCellera Biologics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for AbCellera Biologics this week, compared to 4 articles on an average week.
  • Search Interest

    24 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.90% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AbCellera Biologics' insider trading history.
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Stock News Headlines

Q2 Earnings Forecast for ABCL Issued By Leerink Partnrs
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

ABCL Stock Analysis - Frequently Asked Questions

AbCellera Biologics' stock was trading at $2.93 on January 1st, 2025. Since then, ABCL shares have increased by 36.9% and is now trading at $4.01.

AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02. The firm had revenue of $4.24 million for the quarter, compared to analysts' expectations of $7.12 million. AbCellera Biologics had a negative net margin of 737.56% and a negative trailing twelve-month return on equity of 15.98%.
Read the conference call transcript
.

AbCellera Biologics (ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

AbCellera Biologics' top institutional shareholders include GEM Asset Management LLC (0.01%) and Salem Investment Counselors Inc. (0.01%). Insiders that own company stock include Holdings Ltd Thermopylae and Andrew Booth.
View institutional ownership trends
.

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/08/2025
Today
7/11/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABCL
CIK
1703057
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$5.00
Potential Upside/Downside
+87.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$162.86 million
Net Margins
-737.56%
Pretax Margin
-911.23%
Return on Equity
-15.98%
Return on Assets
-12.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.15
Quick Ratio
10.15

Sales & Book Value

Annual Sales
$28.83 million
Price / Sales
41.51
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.58 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
298,420,000
Free Float
212,179,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.62
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ABCL) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners